Pfizer Inc. shares fell 2% Tuesday despite the drugmaker topping Wall Street’s revenue and profit estimates in its ...

Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as ...

(Reuters) -Drugmaker Pfizer posted a better than expected fourth quarter profit on Thursday, helped by cost cuts and a ...

Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (OTC:ALPMF) (OTC:ALPMY) released additional follow-up results from the Phase ...

Pfizer faces stagnant revenue and patent cliffs. Learn why I downgraded PFE stock to Strong Sell despite a 24.7% YoY growth ...

Eliquis, a blood thinner marketed in partnership with Bristol Myers Squibb, is Pfizer's largest revenue stream at the moment.

Pfizer's adjusted EPS of $0.63 surpassed the expected $0.47. Revenue reached $17.8 billion, exceeding the anticipated $17.35 ...

Pfizer on Tuesday reported fourth-quarter earnings and revenue that beat estimates as sales of the company's Covid products ...

Pfizer Inc (PFE) reports robust financial performance with significant revenue growth and strategic progress in oncology and ...

For 2025, Pfizer forecast revenue between $61 billion and $64 billion, as well as adjusted earnings per share in the range of $2.80 to $3.00. Analysts polled by FactSet expect $63.07 billion in ...

Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...

Pfizer Inc. shares fell 1.6% Tuesday despite the drugmaker topping Wall Street's revenue and profit estimates in its fourth-quarter results. Analyst firm Edward Jones expects Pfizer's future growth to ...